Lacerta Therapeutics
Fatima Shaerzadeh is a Principal Scientist at Lacerta Therapeutics since March 2021, overseeing senior scientist responsibilities in gene therapy programs. Prior to this role, Fatima served as a Postdoctoral Research Associate at the University of Florida from June 2017 to March 2021. Earlier experience includes a position as an Assistant Professor at Hormozgan University of Medical Sciences from June 2015 to June 2017 and a PhD Student at Neurosciences Research Center, Shahid Beheshti University of Medical Sciences from February 2011 to March 2015. Fatima began academic involvement as a Research Assistant at the same institution in Tehran, Iran, from July 2009 to March 2015.
This person is not in any offices
Lacerta Therapeutics
Lacerta Therapeutics is a clinical stage gene therapy company using a constellation of proprietary adeno-associated virus (AAV) vector technologies to develop treatments for central nervous system and lysosomal storage diseases. With unmatched scientific expertise and depth in the development, production, and application of AAV vectors, LacertaTherapeutics is advancing its clinical programs using its proprietary capsid variants and scalable vector manufacturing platform. The experience and accomplishments of the Lacerta Therapeutics founders are unsurpassed in AAV gene therapy. In addition to world-class basic AAV vector development and gene therapy clinical trial expertise, our team brings to bear individuals with novel insight into developing novel, targeted neurological and lysosomal storage disease treatments.